Standard BioTools Inc.LABNASDAQ
Loading
Year-over-year research & development expense growth
5Y CAGR
-7.6%/yr
Long-term compound
Percentile
P90
Near historical high
vs 5Y Ago
0.7x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 25.38% |
| Q3 2025 | 2.15% |
| Q2 2025 | -45.07% |
| Q1 2025 | -19.39% |
| Q4 2024 | 6.82% |
| Q3 2024 | 81.61% |
| Q2 2024 | -54.67% |
| Q1 2024 | 131.29% |
| Q4 2023 | 8.46% |
| Q3 2023 | 3.01% |
| Q2 2023 | -3.81% |
| Q1 2023 | -23.25% |
| Q4 2022 | -1.28% |
| Q3 2022 | -32.68% |
| Q2 2022 | 42.20% |
| Q1 2022 | 3.79% |
| Q4 2021 | -7.25% |
| Q3 2021 | -2.46% |
| Q2 2021 | -12.20% |
| Q1 2021 | -3.87% |
| Q4 2020 | 37.62% |
| Q3 2020 | -3.79% |
| Q2 2020 | -2.89% |
| Q1 2020 | 5.09% |
| Q4 2019 | 16.18% |
| Q3 2019 | -9.41% |
| Q2 2019 | -6.06% |
| Q1 2019 | 5.20% |
| Q4 2018 | 7.11% |
| Q3 2018 | 0.60% |
| Q2 2018 | 1.79% |
| Q1 2018 | 1.37% |
| Q4 2017 | -6.83% |
| Q3 2017 | 2.98% |
| Q2 2017 | -12.47% |
| Q1 2017 | -2.84% |
| Q4 2016 | -5.18% |
| Q3 2016 | -7.28% |
| Q2 2016 | -4.17% |
| Q1 2016 | 6.90% |